- Home
- NAMI vs VTYX Comparison
NAMI vs VTYX Comparison
Compare NAMI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMI
- VTYX
- Stock Information
- Founded
- NAMI 2014
- VTYX 2018
- Country
- NAMI China
- VTYX United States
- Employees
- NAMI N/A
- VTYX N/A
- Industry
- NAMI
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- NAMI
- VTYX Health Care
- Exchange
- NAMI NYSE
- VTYX Nasdaq
- Market Cap
- NAMI 185.3M
- VTYX 154.9M
- IPO Year
- NAMI 2024
- VTYX 2021
- Fundamental
- Price
- NAMI $0.94
- VTYX $2.90
- Analyst Decision
- NAMI
- VTYX Buy
- Analyst Count
- NAMI 0
- VTYX 4
- Target Price
- NAMI N/A
- VTYX $11.33
- AVG Volume (30 Days)
- NAMI 30.4K
- VTYX 1.2M
- Earning Date
- NAMI 08-12-2025
- VTYX 08-07-2025
- Dividend Yield
- NAMI N/A
- VTYX N/A
- EPS Growth
- NAMI N/A
- VTYX N/A
- EPS
- NAMI 0.10
- VTYX N/A
- Revenue
- NAMI $55,677,960.00
- VTYX N/A
- Revenue This Year
- NAMI N/A
- VTYX N/A
- Revenue Next Year
- NAMI N/A
- VTYX N/A
- P/E Ratio
- NAMI $9.48
- VTYX N/A
- Revenue Growth
- NAMI 7.00
- VTYX N/A
- 52 Week Low
- NAMI $0.86
- VTYX $0.78
- 52 Week High
- NAMI $7.75
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- NAMI N/A
- VTYX 52.00
- Support Level
- NAMI N/A
- VTYX $2.63
- Resistance Level
- NAMI N/A
- VTYX $3.30
- Average True Range (ATR)
- NAMI 0.00
- VTYX 0.22
- MACD
- NAMI 0.00
- VTYX -0.06
- Stochastic Oscillator
- NAMI 0.00
- VTYX 20.83
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The company generates revenue by selling its content to hardware manufacturers in China whereby are allowed to install the company's digital educational content on the manufacturers' devices for sale to end users.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.